B

    BeiGene, Ltd. (ONC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $359.58
    -7.15 (-1.95%)

    Market Cap: $41.49B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    58%(22/38)
    Avg Surprise
    +20.41%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$1.82
    Range$1.56 - $2.11
    11 analysts
    EPS Revisions
    7
    0
    7d
    7
    3
    30d
    EPS Estimate Drift
    90d ago$1.73-5.2%
    60d ago$1.73-5.2%
    30d ago$1.71-5.8%
    7d ago$1.82+0.0%
    Current$1.82
    Revenue Consensus
    $1.8B
    Range$1.7B - $1.8B
    12 analysts
    Dec 31, 2026
    EPS Consensus$3.34
    Range$2.26 - $4.57
    16 analysts
    Revenue Consensus
    $1.9B
    Range$1.9B - $2.0B
    29 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.34---
    Sep 26EST
    		-$1.82---
    Jun 26
    		$2.05$1.40+46.43%Beat+144.0%
    Mar 26
    		$1.96$0.81+141.98%Beat+19500.0%
    Dec 25
    		$0.58N/A-63.75%Miss+140.6%
    Sep 25
    		$1.09$0.86+26.74%Beat+194.8%
    Jun 25
    		$0.84$0.26+223.08%Beat+173.0%
    Mar 25
    		$0.01N/A+101.35%Beat+100.4%
    Dec 24
    		$-1.43$-1.01-41.58%Miss+58.9%
    Sep 24
    		$-1.15$-1.11-3.60%Miss-157.2%
    Jun 24
    		$-1.15$-2.14+46.26%Beat+68.4%
    Mar 24
    		$-2.41$-2.92+17.47%Beat+27.8%
    Dec 23
    		$-3.48$-3.45-0.87%Miss+18.9%
    Sep 23
    		$2.01$-2.93+168.60%Beat+137.3%
    Jun 23
    		$-3.64$-2.98-22.15%Miss+34.5%
    Mar 23
    		$-3.34$-3.66+8.74%Beat+21.2%
    Dec 22
    		$-4.29$-4.35+1.38%Beat+30.4%
    Sep 22
    		$-5.39$-3.77-42.97%Miss-20.9%
    Jun 22
    		$-5.56$-4.01-38.65%Miss-6.3%
    Mar 22
    		$-4.24$-4.47+5.15%Beat-714.5%
    Dec 21
    		$-6.16$-6.16+0.00%Beat-18.5%
    Sep 21
    		$-4.46$-4.70+5.11%Beat+7.3%
    Jun 21
    		$-5.23$-3.99-31.08%Miss-21.3%
    Mar 21
    		$0.69N/A+141.82%Beat+114.7%
    Dec 20
    		$-5.20$-5.20+0.00%Beat+18.6%
    Sep 20
    		$-4.81$-4.18-15.07%Miss+5.9%
    Jun 20
    		$-4.31$-4.72+8.69%Beat-201.4%
    Mar 20
    		$-4.70$-4.85+3.09%Beat-67.3%
    Dec 19
    		$-6.39$-6.39+0.00%Beat-41.4%
    Sep 19
    		$-5.11$-3.56-43.54%Miss-102.0%
    Jun 19
    		$-1.43N/A+52.49%Beat+51.0%
    Mar 19
    		$-2.81$-3.14+10.51%Beat-38.4%
    Dec 18
    		$-4.52$-2.79-62.01%Miss-170.5%
    Sep 18
    		$-2.53$-2.97+14.81%Beat-199.6%
    Jun 18
    		$-2.92$-2.12-37.74%Miss-92.1%
    Mar 18
    		$-2.03$-1.74-16.67%Miss-59.8%
    Dec 17
    		$-1.67N/AN/ABeat-166.9%
    Sep 17
    		$2.54$-1.39+282.73%Beat+335.2%
    Jun 17
    		$-1.52$-1.20-26.67%Miss-
    Mar 17
    		$-1.27$-0.87-45.98%Miss-
    Dec 16
    		$-0.63N/AN/ABeat-
    Sep 16
    		$-1.08$-0.78-38.46%Miss-

    Key Metrics

    Valuation
    P/E Ratio63.31EV/EBITDA35.05x
    Price/FCF33.51xFCF Yield2.98%
    Profitability
    Profit Margin10.70%Operating Margin19.10%
    ROE14.70%ROIC12.15%
    Financial Health
    Debt/Equity0.21xInterest Coverage6.84x
    Current Ratio3.40xQuick Ratio3.06x
    Trading Statistics
    Beta0.50Avg Volume401.60K
    52-Week High$385.2252-Week Low$253.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$371.26
    SMA 20$359.23
    SMA 50$326.77
    SMA 200$318.14
    EMA 10$366.64
    EMA 20$358.11
    EMA 50$335.93
    EMA 200$314.72

    MACD

    Line: 12.75Signal: 14.65Hist: -1.90

    ADX

    ADX: 32.0+DI: 32.6-DI: 29.8

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down20.0
    PSAR$379.69

    Bollinger Bands

    Upper Band$392.20
    Lower Band$326.25
    %B Position1836%(Upper)
    Band Width0.51

    RSI (14-Day)

    Neutral
    55.7

    Momentum Oscillators

    Stoch %K62.4
    Stoch %D75.7
    Williams %R-55.9
    ROC (10d)-0.8%
    Momentum-2.93
    CCI (20d)-5.2
    MFI (14d)44.1

    Volatility Measures

    ATR (14d)$9.46(2.6%)
    StdDev (20d)16.49
    Hist Vol34.5%(Moderate)

    Volume Flow

    VWAP$357.82
    OBV4.8M
    AD Line1.1M
    CMF (20d)0.132

    Volume Metrics

    Avg Vol (20d)403.7K
    Vol Ratio0.8x
    VWMA (20d)$358.01

    Pivot Points

    R3$378.18
    R2$375.09
    R1$370.91
    Pivot Point$367.82
    S1$363.64
    S2$360.55
    S3$356.37

    Advanced Oscillators

    TSI33.78
    Ultimate Osc55.0
    KST161.80

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.71B$1.51B$1.50B$1.41B$1.32B$1.12B$1.13B$1.00B$929.17M$751.65M$634.41M$781.31M
    Cost of Revenue$174.53M$167.22M$142.42M$196.51M$164.61M$165.00M$160.56M$170.46M$138.13M$124.94M$105.83M$96.31M
    Gross Profit$1.53B$1.35B$1.36B$1.22B$1.15B$952.28M$967.26M$831.14M$791.03M$626.72M$528.58M$685.00M
    Operating Expenses$1.21B$1.10B$1.17B$1.05B$1.06B$941.17M$1.05B$951.40M$898.20M$888.07M$912.37M$818.97M
    R&D$612.28M$541.22M$615.42M$523.66M$524.90M$481.89M$542.01M$496.18M$454.47M$460.64M$493.99M$453.26M
    SG&A$593.21M$555.10M$555.29M$529.00M$537.91M$459.27M$504.68M$455.22M$443.73M$427.43M$416.55M$365.71M
    Operating Income$325.05M$249.90M$185.03M$163.11M$87.89M$11.10M$-79,425,000$-120,265,000$-107,161,000$-261,348,000$-383,795,000$-133,968,000
    Interest Income$27.90M$27.66M$58.13M$3.03M$3.50M$5.85M$7.81M$10.64M$13.22M$16.16M$0$26.65M
    Interest Expense$39.74M$32.89M$58.23M$15.95M$8.00M$7.00M$5.93M$0$0$0$0$0
    Income Before Tax$312.46M$259.21M$149.24M$147.16M$99.55M$20.90M$-85,351,000$-98,304,000$-105,920,000$-243,426,000$-350,772,000$229.34M
    Income Tax Expense$75.45M$31.86M$82.74M$22.32M$5.23M$19.63M$66.53M$23.05M$14.48M$7.72M$16.78M$13.93M
    Net Income$237.01M$227.36M$66.50M$124.84M$94.32M$1.27M$-151,881,000$-121,350,000$-120,405,000$-251,150,000$-367,553,000$215.41M
    EBITDA$392.71M$333.25M$248.97M$184.45M$135.16M$60.71M$-35,105,000$-27,012,000$-81,810,000$-218,133,000$-326,953,000$250.85M
    EBIT$352.20M$292.10M$212.99M$147.16M$99.55M$27.90M$-85,351,000$-98,304,000$-105,920,000$-243,426,000$-350,772,000$229.34M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ONC

    News

    BeOne Medicines receives FDA approval for TEVIMBRA and ZIIHERA regimen

    BeOne Medicines received FDA approval for TEVIMBRA combined with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. This approval is based on Phase 3 HERIZON-GEA-01 trial results, which showed a median overall survival of 26.4 months compared to 19.2 months for the control arm. This expands TEVIMBRA’s use in the first-line treatment of advanced HER2-positive gastric, gastroesophageal junction, and esophageal adenocarcinoma, marking it as the company's first approved solid tumor portfolio asset.

    grafa.com•8/25/26•
    Bullish

    RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $450

    RBC Capital has reiterated its Buy rating on BeiGene (ONC.US) and maintained its target price at $450. This indicates a continued positive outlook from the firm regarding BeiGene's stock performance.

    Moomoo•8/25/26•
    Bullish

    BeiGene (06160.HK) will release its financial report on August 26.

    BeiGene (06160.HK) announced that it will release its interim financial report for the six months ended June 30, 2026, on Monday, August 26, 2026. The announcement will be made after the market close in Hong Kong and before the market opens in the U.S.

    Moomoo•8/20/26•
    Neutral

    BeiGene(ONC.US) Officer Sells US$86.48 Million in Common Stock

    This article reports that a BeiGene (ONC.US) officer sold common stock totaling US$86.48 million.

    Moomoo•8/13/26•
    Bearish

    BOCOM International: BeiGene maintains 'Buy' rating with target price raised to HK$276

    BOCOM International has maintained its 'Buy' rating for BeiGene, increasing the target price to HK$276. This reflects a positive outlook on the biopharmaceutical company's future performance and valuation.

    富途牛牛•8/10/26•
    Bullish

    Frequently Asked Questions About ONC

    Does ONC pay dividends?
    BeiGene, Ltd. (ONC) does not currently pay a regular dividend.
    What is ONC's P/E ratio?
    BeiGene, Ltd. has a price-to-earnings (P/E) ratio of 63.31.
    What is ONC's market cap?
    BeiGene, Ltd. (ONC) has a market capitalization of $41.49B with a current stock price of $359.58.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In